<DOC>
	<DOCNO>NCT02191540</DOCNO>
	<brief_summary>Phase 3 , non-randomized , Multicenter , single arm study ass efficacy safety Abnoba viscum F 20mg patient malignant pleural effusion</brief_summary>
	<brief_title>Efficacy Safety Study Abnoba Viscum F 20mg Malignant Pleural Effusion Patients</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>Subject need pleurodesis among subject diagnose mlignant pleural effusion Full lung expansion must achieve within 12 24 hour drainage Expected survival time least 2 month Subject score 50 Karnofsky Performance Scale Subjects previous attempt pleurodesis sclerosing agent Subjects trap lung bronchial obstruction Subjects adverse drug response mistletoe agent Subjects participate another clinical study present study Subjects take immunesuppressive agent Subjects medical psychiatric contraindication study drug Subjects allow participate study legal requirement Subjects allow participate study Investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>